<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647697</url>
  </required_header>
  <id_info>
    <org_study_id>UP0027</org_study_id>
    <secondary_id>2015-004376-29</secondary_id>
    <nct_id>NCT02647697</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers</brief_title>
  <official_title>A Single Oral Dose Study of the Safety, Tolerability, and Pharmacokinetic Profile of Radiprodil in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics (PK) profile of Radiprodil in suspension form in healthy
      adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      UP0027 is a Phase 1, single-center, open-label study to investigate the safety, tolerability,
      and PK profile of radiprodil in healthy adult male and female subjects after a single fasting
      oral dose of radiprodil 30 mg suspension formulation. A total of 10 subjects will be enrolled
      in the study.

      The primary objective of the study is to evaluate the PK profile of oral radiprodil in
      suspension form in healthy adult subjects.

      The secondary objective of the study is to evaluate the safety and tolerability of oral
      radiprodil in suspension form in healthy adult subjects.

      The exploratory objectives of the study are to evaluate the comparative PK profile of
      radiprodil from samples collected using 2 alternative microsampling techniques (MITRA™ and
      Drummond capillary tubes) with that of conventional venous blood samples, and to test the
      perception of the taste and texture of the oral radiprodil suspension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the concentration-time curve of Radiprodil from dosing to time t (AUC(0-t))</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
    <description>The area under the concentration-time curve of Radiprodil from dosing to time t (AUC(0-t)) is computed from plasma concentrations of pharmacokinetic samples taken predose and 0.5h, 1h, 1.5h, 2 h, 2.5h, 3 h, 3.5h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose using non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent terminal elimination half-life of Radiprodil (t1/2)</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum observed plasma concentration of Radiprodil (Cmax)</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
    <description>The Cmax is the maximum plasma concentration of radiprodil observed from pharmacokinetic samples taken predose and 0.5h, 1h, 1.5h, 2 h, 2.5h, 3 h, 3.5h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time of occurrence of Cmax of Radiprodil (Tmax)</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
    <description>Time to reach maximum plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The volume of distribution of Radiprodil (Vd)</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the concentration-time curve from dosing extrapolated to infinity of Radiprodil (AUC)</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
    <description>The area under the concentration-time curve of Radiprodil from dosing extrapolated to infinity (AUC) is computed from plasma concentrations of pharmacokinetic samples taken predose and 0.5h, 1h, 1.5h, 2 h, 2.5h, 3 h, 3.5h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose dose using non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The individual estimate of the terminal elimination rate constant of Radiprodil (λz)</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent total body clearance of Radiprodil (CL/F)</measure>
    <time_frame>Blood samples will be taken pre-dose on Day 1 and 0.5 h, 1 h, Pre-dose, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, and 48 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting at least one treatment-emergent Adverse Event (AE) during the study</measure>
    <time_frame>From Day 1 to Day 15</time_frame>
    <description>Treatment-emergent adverse event is an adverse event starting after the first study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Radiprodil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of Radiprodil 30 mg in suspension form, orally via a syringe in the morning of Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiprodil oral</intervention_name>
    <description>Active Substance: Radiprodil
Pharmaceutical Form: dry granules for oral suspension
Concentration: 30 mg
Route of Administration: oral use</description>
    <arm_group_label>Radiprodil</arm_group_label>
    <other_name>UCB3491</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female, ≥ 18 years to ≤ 45 years of age

          -  Subject smokes &lt; 10 cigarettes per day and has a score of &lt; 4 on the Fagerström Test
             for Nicotine Dependence (Heatherthon et al., 1991). The Fagerström Test is not
             required for nonsmokers (ie, no smoking for at least 6 months)

          -  Subject has a body mass index (BMI) of 18 to 30 kg/m² (inclusive), with a body weight
             of at least 50 kg (male) or 45 kg (female)

          -  Subject has a blood pressure and pulse rate within the normal range in supine position
             after 5 minutes rest (systolic blood pressure: 90 mmHg to 140 mm Hg, diastolic blood
             pressure: 45 mmHg to 90 mmHg, pulse rate: 45 bpm to 90 bpm)

        Exclusion Criteria:

          -  Subject has a known hypersensitivity to any components of Radiprodil liquid
             formulation including the excipients or a history of drug or other allergy that, in
             the opinion of the Investigator or UCB Study Physician, contraindicates his/her
             participation

          -  Subject has received prescription or nonprescription medicines (including
             over-the-counter medicines and herbal and dietary supplements [including St John's
             Wort]) within 14 days. Exceptions:

               -  Paracetamol for the treatment of mild symptoms (eg, headache or other pain),
                  given at most every 6 h to 8 h, not exceeding 2 g/day, and with a total of no
                  more than 5 g over 7 days

               -  Inhaled corticosteroids for seasonal rhinitis

               -  Vitamins within recommended daily dose Limits

          -  Subject has consumed any grapefruit, grapefruit juice, grapefruit-containing products,
             or star fruit within 14 days prior to administration of Radiprodil

          -  Subject has a history of unexplained syncope or a family history of sudden death due
             to long QT syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up002700001</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UCB3491</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Radiprodil</keyword>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

